Which meeting are you claiming credit for?
*
Wednesday, March 13th, 2024 – University Hospital of Lausanne
Tuesday, April 2nd, 2024 - Hospital de Santa Marta, Lisbon
Monday, April 22nd, 2024 - HUB Erasme Hospital, Brussels
Tuesday, April 23rd, 2024 - St George's University of London
Wednesday, April 24th, 2024 - University of Trieste
Monday, May 20th, 2024 - Harefield Hospital, Royal Brompton and Harefield Hospitals
Tuesday, May 21st, 2024 - Hôpital Européen Georges Pompidou, Paris
Wednesday, May 22nd, 2024 - University of Bologna
Wednesday, May 29th, 2024 - Fondazione Toscana Gabriele Monasterio, Pisa, Italy
Wednesday, July 17th, 2024 - Semmelweis University
Date 1
Date 2
Date 3
Date 4
Date 5
Date 6
Date 7
Date 8
Date 9
Date 10
Name
*
First Name
Last Name
Degree(s)
*
Email
*
example@example.com
Institution
Country
1. What are the diagnostic criteria for hypertrophic cardiomyopathy (HCM) in adults?
*
a. Left ventricular (LV) wall thickness > than 2 SD > predicted mean
b. LV wall thickness ≥13 mm in any myocardial segment not explained by loading conditions
c. LV wall thickness ≥15 mm in any myocardial segment not explained by loading conditions
d. LV wall thickness ≥13 mm in lateral myocardial segments not explained by loading conditions
2. What is the recommended frequency to follow asymptomatic HCM patients with echocardiography?
*
a. Every 6 months
b. Every 1-2 years
c. Every 5th year
d. Not necessary before they get symptoms
3. What are the advantages of cardiac magnetic resonance imaging (CMR) compared to echocardiography in HCM patients? (Multiple answers might be correct)
*
a. Better assessment of left ventricular outflow tract (LVOT) gradient
b. Tissue characterization
c. The ability to discover increased wall thickness around different parts of the LV
d. Better assessment of diastolic function
4. What is the most common treatable cause of heart failure symptoms in HCM?
*
a. End-stage progression
b. MINOCA
c. Left ventricular outflow obstruction
d. Paroxysmal atrial fibrillation
5. What is mavacamten?
*
a. A cardiac myosin activator
b. A cardiac myosin inhibitor
c. A phosphodiesterase inhibitor
d. A SGLT2-inhibitor
6. What is the class of recommendation for mavacamten in the 2023 ESC Guidelines for diagnosis and management of cardiomyopathies?
*
a. I a
b. I b
c. II a
d. II b
Learning Objectives
Rows
Poor
Fair
Good
Very Good
Excellent
An improved understanding of the prevalence, pathophysiology, unmet patient needs, and natural course of HCM
Improved confidence and competence in diagnostic skill for recognizing HCM
A clear understanding of the differences between symptom management and pathophysiology-targeted treatment for patients with HCM
Practice-pertinent awareness of the most recent clinical data on the efficacy and safety of CMIs in the management of HCM
Familiarity with the most current specialty society guidelines addressing the management of HCM
Do you feel this activity was fair balanced and free of commercial bias?
Yes
No
If no, please explain:
This educational activity will result in a change in my role as a healthcare team member.
Yes
No
N/A
This educational activity will result in a change in my practice behavior.
Yes
No
N/A
Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
I gained new strategies/skills/information that my team can apply to practice
I plan to implement new strategies/skills/information in my practice
I will be more competent in my team’s management of patient care
I will improve my communication with the healthcare team
What factors beyond clinical care that effect the health of your patients does your team experience?
Submit
Should be Empty: